Data Insights

Toripalimab by Coherus BioSciences for Chondrosarcoma: Likelihood of Approval

Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Chondrosarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Chondrosarcoma

Data Insights

Toripalimab by Coherus BioSciences for Soft Tissue Sarcoma: Likelihood of Approval

Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Soft Tissue Sarcoma

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Metastatic Biliary Tract Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Metastatic Biliary Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Metastatic Biliary Tract Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Urethral Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Urethral Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Urethral Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Ureter Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Ureter Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Ureter Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Prostate Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Prostate Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Prostate Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Cervical Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Cervical Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Bladder Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Bladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Bladder Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Hypopharyngeal Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Hypopharyngeal Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Laryngeal Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Laryngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Laryngeal Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Metastatic Colorectal Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Hepatocellular Carcinoma: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Hepatocellular Carcinoma

Data Insights

Toripalimab by Coherus BioSciences for Solid Tumor: Likelihood of Approval

Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Solid Tumor

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Anal Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Anal Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Ewing Sarcoma: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Ewing Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Ewing Sarcoma

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Neuroendocrine Carcinoma: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Neuroendocrine Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Neuroendocrine Carcinoma

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Throat Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Throat Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Throat Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Rhabdomyosarcoma: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Rhabdomyosarcoma

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Oropharyngeal Cancer: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Oropharyngeal Cancer

Data Insights

Toripalimab by Shanghai Junshi Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....

Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Adenocarcinoma Of The Gastroesophageal Junction